Romeo R. Dizon, the chief financial officer of Iridex Corporation (NASDAQ: IRIX), acquired 1,101 shares of the company’s common stock at a price of $1.442 per share on January 29, 2026, for a total transaction value of $1587. Following the purchase, Dizon directly owns 112,690 shares of Iridex.
Separately, the company released preliminary unaudited results for the fourth quarter indicating revenue between $14.6 million and $14.8 million. Those figures represent a year-over-year increase in the range of 15% to 17%. Iridex also reported it generated positive cash flow during the quarter and said it expects to record a positive adjusted EBITDA for the full year of 2025.
Clinical research published in Ophthalmology and Therapy was cited in the company updates. The independent study assessed Iridex’s MicroPulse transscleral laser technology used for retreatment in glaucoma patients and reported intraocular pressure reductions of approximately 25% to 35%.
These recent developments sit alongside the company's previously reported third-quarter results for 2025. In Q3 2025, Iridex posted a net loss of $1.6 million, or $0.09 per share, which fell short of analyst expectations for a $0.06 loss per share. Revenue for the third quarter was $12.5 million, below the anticipated $13.1 million.
Taken together, the insider purchase and the preliminary fourth-quarter figures add to the company's recent disclosure trail: improving top-line momentum and positive cash generation in Q4 as set against a third-quarter shortfall and ongoing clinical evaluations of its technology. The company has emphasized continued work on its treatments and technology advancements.
Key points
- Iridex CFO Romeo R. Dizon bought 1,101 shares at $1.442 per share on January 29, 2026, totaling $1587 and increasing his direct ownership to 112,690 shares.
- Preliminary unaudited Q4 revenue came in between $14.6 million and $14.8 million, a 15% to 17% increase year-over-year, with positive cash flow reported for the quarter and an expectation of positive adjusted EBITDA for full-year 2025.
- An independent study published in Ophthalmology and Therapy found that MicroPulse transscleral laser retreatment produced intraocular pressure reductions of roughly 25% to 35% for glaucoma patients.
Risks and uncertainties
- Recent financial performance is mixed - Q3 2025 showed a $1.6 million net loss and revenue short of expectations, indicating potential volatility in near-term results. (Affected sectors: healthcare equipment, small-cap equities)
- Preliminary Q4 results are unaudited; final audited results could differ from the ranges reported. (Affected sectors: investor markets, healthcare finance)
- Clinical findings cited are from an independent study; broader clinical adoption and commercial impact are not quantified in the company disclosures. (Affected sectors: medical devices, ophthalmology)